Mouse Monoclonal DLL4 Antibody

The Delta-like ligand 4 (DLL4) antibody targets DLL4. a key ligand in the Notch signaling pathway, which plays a critical role in regulating cell differentiation, proliferation, and angiogenesis. DLL4 is predominantly expressed in endothelial cells and certain tumor cells, where it binds to Notch receptors (Notch1/Notch4) to coordinate vascular development and maintenance. Its involvement in pathological angiogenesis, particularly in cancers, has made it a therapeutic focus. By blocking DLL4-Notch interactions, DLL4 antibodies inhibit tumor-associated angiogenesis, disrupting the formation of functional vasculature and starving tumors of nutrients. This approach has shown promise in preclinical models of solid tumors, including colorectal and ovarian cancers. However, DLL4 inhibition may also trigger compensatory mechanisms, such as increased VEGF expression, necessitating combination therapies. Beyond oncology, DLL4 antibodies are explored in ischemic diseases to modulate abnormal vessel growth. Current research addresses challenges like on-target toxicity (e.g., vascular hyperplasia) and optimal dosing. Several DLL4-targeting agents, including demcizumab and enoticumab, have entered clinical trials, though efficacy and safety data remain under evaluation. Understanding DLL4's dual roles in physiological and pathological contexts continues to drive innovation in antibody engineering and therapeutic strategies.